JP4589483B2 - Acne preventive and therapeutic agent - Google Patents
Acne preventive and therapeutic agent Download PDFInfo
- Publication number
- JP4589483B2 JP4589483B2 JP2000140031A JP2000140031A JP4589483B2 JP 4589483 B2 JP4589483 B2 JP 4589483B2 JP 2000140031 A JP2000140031 A JP 2000140031A JP 2000140031 A JP2000140031 A JP 2000140031A JP 4589483 B2 JP4589483 B2 JP 4589483B2
- Authority
- JP
- Japan
- Prior art keywords
- acne
- extract
- therapeutic agent
- stratum corneum
- leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、角層の剥離を促進し、ニキビの予防及び治療等に有効なニキビ予防治療剤及び角層剥離促進剤に関する。
【0002】
【従来の技術及び発明が解決しようとする課題】
ニキビ(尋常性座瘡)は、主として思春期の男女の顔面、上腕部、背部あるいは上腕伸側などに発生し、その発生頻度は食生活を含め生活環境の著しい変化や性の熟成化の低年齢化等により年々高くなっている。また、重症のニキビは治癒後に痕跡を残すことが多く、精神的に日常生活や社会生活に影響を及ぼすことも少なくない。
【0003】
ニキビの発症には、皮脂分泌亢進とその貯留、毛包管の角化亢進と閉塞、毛包管内におけるPropionibacterium acnes などの細菌増殖等、いくつかの因子が相互に関連すると考えられている。特に最近では角層剥離機構が解明され、層板顆粒中に内包されるプロテアーゼ群の機能が低下することにより角層の剥離が遅延し、毛包の管膣内に角化物の堆積が生じることによりニキビが形成されると考えられている。
【0004】
一方、これまでのニキビの予防及び治療法は、角質剥離の促進を目的として硫黄あるいはサリチル酸を含むローション剤よる外用療法とテトラサイクリン系あるいはセフェム系抗生剤等の投与による全身療法が中心であった。
しかし、外用療法では、充分な効果が得られず、さらに多用によって刺激を生じやすいという問題があり、全身療法に関しては、長期投与による胃腸障害、肝障害、色素沈着、発疹の発現などの副作用を示す場合があり、また、妊娠やその可能性のある婦人に対して用いることはできないという問題もあった。
【0005】
本発明の目的は、日常のスキンケアの段階からニキビを予防すると共にニキビ治療に有効で且つ人体に対する安全性の高い医薬又は化粧料を提供することにある。
【0006】
【課題を解決するための手段】
本発明者らは、角質細胞の剥離に関わるプロテアーゼの量的な変化に着目し検討したところ、ある種の動植物抽出物が培養表皮細胞のカテプシンDの量を増加させることを見出し、これらを配合した組成物が、角層の剥離を促進すると共に優れたニキビ予防治療効果を発揮することを見出し、本発明を完成した。
【0007】
すなわち、本発明は、アカメガシワ、カロコン、ゴシツ、サンキライ、ハンゲ、セネガ、ショウブ、スイカズラ、ムクロジ、ブッチャーブルーム、キキョウ、ハマボウフウ、トマト、ヘチマ、アボカド、キナ、セイヨウネズ、レタス、イリス、コウホネ、シイタケ、トウガラシ及びメリロートから選ばれた1種以上の植物抽出物からなるニキビ予防治療剤又は角層剥離促進剤を提供するものである。
【0008】
【発明の実施の形態】
本発明の(A)植物抽出物における植物とは、アカメガシワ(Mallotus japonicus MUELL、トウダイグサ科)、ウワウルシ(Arctostaphylos uwa-ursi Sprengel、ツツジ科)、カロコン(Trichosanthes kirilowii Maximocz、キカラスウリ Trichosanthes kirillowii Maximocz var.japonicum kitamura、又はオオカラスウリ Trichosanthes bracteata Voigt、ウリ科)、ゴシツ(ヒナタイノコズチ Achyranthes fauriei Leveille又はAchyranthes bidentata Blume、ヒユ科)、サンキライ(Smilax glabra Roxburgh、ユリ科)、ハンゲ(カラスビシャク Pinellia ternata Breitenbach、サトイモ科)、セネガ(Polygala senega L.、ビメハギ科)、ショウブ(Acorus Calamus L.、サトイモ科)、スイカズラ(Lonicera japonica Thunb.、スイカズラ科)、ムクロジ(Sapindus mukurossi Gaertn.、ムクロジ科)、アスパラサスリネアリス(Aspalathuslinearis R.Dahlgr、マメ科)、ブッチャーブルーム(ナギイカダ Ruscus aculeatus L.、ユリ科)、エンゴサク(Corydalis turtschaninouii Besser又はその他同属植物、ケシ科)、キキョウ(Platycodon grandinorum A.De Candolle、ケシ科)、ハマボウフウ(Glehnia Littoralis Fr. Schmidt、セリ科)、シコン(ムラサキ Lithospermum erythrorhizon Siebold、ムラサキ科)、トマト(Lycopersicum esculentum Mill.、ナス科)、ヘチマ(Luftacyundrbca Roem.、ウリ科)、レモン(Citrus limon Burmann fil.、ミカン科)、アルテア(ビロウドアオイ Althaea officinalis L.、アオイ科)、カッコン(クズ Pueraria lobata ohwi、マメ科)、セイヨウサンザシ(Crataeus oxyacantha L.、バラ科)、トウキンセンカ(Calendula officinalis L.、キク科)、ハマメリス(Hamamelis virginiana L.、マンサク科)、ブドウ(Vitis vinifera L.、ブドウ科)、ボダイジュ(Tilla cordata Miller、シナノキ科)、メリッサ(コウスイハッカ Melissa officinalis L.、シソ科)、マロニエ(セイヨウトチノキ Aesculus Hippocastanum L.、トチノキ科)、アボカド(Persea americana Mill.、クスノキ科)、キナ(キナノキ Cinchona succirubra Pavon et Klotzch又はその他同属植物、アカネ科)、セイヨウネズ(Juniperus communis L.、ヒノキ科)、イザヨイバラ(Rosaroxburghii Tratt. F. Jormalis Rehd et Wils、バラ科)、レタス(Lactuca sativa L、キク科)、イリス(Iris florentina L.、アヤメ科)、コウホネ(Nuphar japonicum DC.、スイレン科)、シイタケ(Lentinas ebobes Singer、マツタケ科)、ツボクサ(Centella asiatica L.、セリ科)、トウガラシ(Capsicum annuum L.、ナス科)、メリロート(Melilotus officinalis L.、マメ科)を示す。
【0009】
これら植物の使用部位は、アカメガシワの樹皮、ウワウルシの葉、カロコンの皮層を除いた根、ゴシツの根、サンキライの塊根、ハンゲのコルク層を除いた塊根、セネガの根、ショウブの根茎、スイカズラの花・葉及び茎、ムクロジの果実、アスパラサスリネアリスの全草、ブッチャーブルームの根茎、エンゴサクの塊根、キキョウの根、ハマボウフウの根及び根茎、ムラサキの根、トマトの果実(生)、ヘチマの果実(生)、レモンの果実(生)、アルテアの根及び葉、カッコンの周皮を除いた根、セイヨウサンザシの花・葉及び果実、トウキンセンカの花、ハマメリスの葉・枝及び樹皮、ブドウの葉、ボダイジュの花、メリッサの葉、マロニエの葉及び樹皮、アボカドの果実(生)、キナノキの樹皮、セイヨウネズの果実、イザヨウバラの果実、レタスの葉、イリスの根茎、コウホネの根茎、シイタケの子実体、ツボクサの葉及び茎、トウガラシの果実、メリロートの地上部が好ましい。
また、適当な抽出溶剤を浸漬又は加熱還流し、適宜濾過、濃縮、凍結乾燥して、濃縮エキスや乾燥粉末等として得ることができる。
【0010】
抽出溶剤としては、メタノール、エタノール、プロパノール、ブタノール、エーテル、エチレングリコール、プロピレングリコール、ブチレングリコール、ヘキサン、ヘプタン、シクロヘキサン、酢酸エチル、アセトン、トルエン、ジクロロエタン、クロロホルム等の一般に用いられる有機溶剤、及び水等を挙げることができ、これらの1種を単独で又は2種以上を混合して使用することができる。これらの溶媒の中では極性溶剤が好ましく、特にエタノール、水、プロピレングリコール、ブチレングリコールがより好ましい。
【0011】
抽出処理は、通常3〜100℃程度の温度で数時間〜数週間、常法によって行うことができ、抽出物からの有効成分の分離精製は、抽出物をゲル濾過、カラムクロマトグラフィー、精密蒸留等で精製することによって行うことができる。
【0012】
本発明の(B)クロレラ抽出物におけるクロレラとは、オオシスティス科(Oocystaceae) クロレラ属(Chlorella) に分類される直径3〜10ミクロンのほぼ球形の単細胞緑藻をいい、その種は特に限定されないが、例えばクロレラ・ブルガリス(Chlorella vulgaris)、クロレラ・ピレノイドサ(Chlorella pyrenoidosa )、クロレラ・レギュラリス(Chlorella regularis )等が挙げられ、中でもクロレラ・ブルガリスが好ましい。
クロレラ抽出物は、クロレラ藻体(全藻)を上記の植物抽出法に準じて抽出することにより得ることができるが、特に水、エタノール、または両者の混合溶媒を用いて抽出、濃縮することが好ましい。
【0013】
本発明の(C)胎盤抽出物としては、ウシ、ブタ又はヒト等の哺乳動物の胎盤を洗浄、除血、破砕、凍結等の手段を経て、水溶性成分を抽出した後、更に不純物を除去して得られるものが挙げられる。これらは、水溶性プラセンタエキスとして一般に市販され、化粧品原料として使用されているが、ニキビ予防治療の観点からは牛胎盤抽出物が好ましい。
【0014】
かくして得られる本発明の抽出物(A)〜(C)は、後記実施例に示すように表皮細胞の層板顆粒由来プロテアーゼであるカテプシンDの産生促進作用を有し、角層の剥離を促進すると共に実験的ニキビの形成を抑制する。従って、当該抽出物を配合した製剤は、ニキビの予防及び治療を目的とした医薬又は化粧料として有用である。
【0015】
本発明のニキビ予防治療剤又は角層剥離促進剤を医薬として使用するする場合には、錠剤、カプセル剤、軟膏、水剤、エキス剤、ローション剤、乳剤等とすることができ、中でも外用医薬品としての使用が好ましい。例えば軟膏剤とする場合には、油性基剤をベースとするもの、水中油型又は油中水型の乳化系基剤をベースとするもののいずれであってもよく、油性基剤としては、例えば植物油、動物油、合成油、脂肪酸及び天然又は合成のグリセライド等が挙げられる。
【0016】
また、当該医薬には、他の薬効成分、例えば鎮痛消炎剤、殺菌消毒剤、収斂剤、皮膚軟化剤、ホルモン剤等を必要に応じて適宜配合することができる。
【0017】
化粧料として使用する場合は、本発明の抽出物の他に、化粧料成分として一般に使用されている油分、界面活性剤、紫外線吸収剤、美白剤、アルコール類、キレート剤、pH調整剤、防腐剤、増粘剤、色素類、香料、各種皮膚栄養剤等を任意に組合せて配合することができる。
【0018】
また、化粧料は、種々の形態、例えば、油中水型又は水中油型の乳化化粧料、クリーム、ジェル、化粧乳液、化粧水、油性化粧料、洗顔料、ファンデーション、パック等とすることができる。
【0019】
医薬又は化粧料における有効成分の配合量は、乾燥物としてとして通常全組成の0.01〜20重量%、特に0.1〜10重量%が好ましい。
【0020】
【実施例】
製造例1 ブッチャーブルーム抽出物の調製
ブッチャーブルーム(ナギイカダ Ruscus aculeatus L.、ユリ科)の根を細切し、その10gに水とエタノールの混液(70:30)100mLを加え、50℃下、ときどき攪拌しながら、5時間抽出した後、ろ過した。これを5℃で7日間静置して熟成させ、生じたオリ及び沈殿をろ過した。これに水とエタノールの混液(70:30)を加え、全体を100mLにした。
【0021】
製造例2
製造例1に準じて、表1に示す各種抽出物100mLを調製した。
また、牛胎盤抽出物は、「ファルコレックスBPS」を用いた。
【0022】
【表1】
【0023】
実施例1 培養表皮細胞のカテプシンDの産生促進作用
正常ヒト表皮細胞(極東製薬)を0.1および1.0%濃度(エキスの添加濃度)の表2に示す各種抽出物で処理し、培地中に遊離する層板顆粒由来プロテアーゼであるカテプシンDをウエスタン・ブロティング法により検出し、そのバンドの強度を対照と比較した。結果を3回試行の平均値として表2に示す。
【0024】
【表2】
【0025】
これより、本発明の各種抽出物は、表皮細胞のカテプシンDの産生を促進することが示され、角層の剥離を促す作用を有することが示唆された。
【0026】
実施例2 ヒト角層に対する剥離促進効果
ヒト腕皮膚に5%ダンシルクロライド溶液を1日間貼付した後,表3に示す各濃度の植物抽出物を9日間塗布し、塗布部での蛍光の強さを目視により判定し、以下に示す評価基準により評価した。結果を表3に示す。
<評価基準>
+++:強い蛍光が全体に認められる
++:蛍光が全体に認められる
+:弱い蛍光が認められる
±:微かな蛍光が認められる
−:蛍光が認められない
【0027】
【表3】
【0028】
表3より、本発明の植物抽出物の塗布により,角層中ダンシルクロライドによる蛍光の消退が認められ,角層の剥離が促進されることが示された。
【0029】
実施例3〜51 実験的ニキビの形成抑制作用
ニュージーランドホワイトラビット153羽(雄、体重2.5kg前後)を51群に分けた(n=3)。各群の左耳外耳道の耳口部には午前中に50%テトラデカンのスクワラン溶液を1回、午後には70%エタノールを1回、綿棒を用いて14日間塗布してコントロール側とした。一方、右耳外耳道の耳口部には午前中に50%テトラデカンのスクワラン溶液を、午後には表4〜6に示す各種抽出物の70%エタノール溶液を同様に塗布してサンプル側とした(各種抽出物の濃度はエキスの蒸発残分濃度(W/V%)で表した)。両側の耳に形成した実験的ニキビをマイクロスコープで観察し、毛孔性皮疹分の面積を測定し(片側10点ずつ)、改善の程度を左右の耳で比較した。結果(左耳に対する右耳の改善の程度)を表4〜6に併せて示す。
【0030】
【表4】
【0031】
【表5】
【0032】
【表6】
【0033】
これより、本発明の抽出物(A)〜(C)は、ニキビの形成を抑制することが示された。
【0034】
【発明の効果】
本発明のニキビ予防治療剤及び角層剥離促進剤は、人体に対する安全性が高く日常のスキンケアの段階から角層の剥離を促進することによりニキビを予防及び治療に有効であり医薬又は化粧料として有用である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an acne preventive and therapeutic agent and a stratum corneum exfoliation accelerating agent that promote exfoliation of the stratum corneum and is effective in preventing and treating acne.
[0002]
[Prior art and problems to be solved by the invention]
Acne (acne vulgaris) occurs mainly on the face, upper arm, back, or upper arm extension of adolescent men and women, and the frequency of occurrence is markedly reduced in the living environment, including eating habits, and low in sexual aging. It is getting higher year by year due to aging. In addition, severe acne often leaves a mark after healing, and it often affects mentally and daily life and social life.
[0003]
The development of acne is thought to be related to several factors such as increased sebum secretion and retention, increased keratinization and obstruction of the follicular tube, and growth of bacteria such as Propionibacterium acnes in the follicular tube. In particular, recently, the stratum corneum peeling mechanism has been elucidated, and the function of the protease group contained in the lamellar granule is reduced, so that the stratum corneum peeling is delayed and the keratin is deposited in the follicle tube vagina. It is thought that acne is formed by.
[0004]
On the other hand, acne prevention and treatment methods so far have mainly focused on topical treatment with a lotion containing sulfur or salicylic acid for the purpose of promoting exfoliation and systemic treatment with administration of tetracycline or cephem antibiotics.
However, there is a problem that external therapy cannot obtain a sufficient effect, and it is easy to cause irritation due to frequent use, and systemic therapy has side effects such as gastrointestinal disorders, liver disorders, pigmentation, and rash caused by long-term administration. There is also a problem that it cannot be used for women who are pregnant or likely to become pregnant.
[0005]
An object of the present invention is to provide a medicament or cosmetic that prevents acne from the daily skin care stage, is effective in treating acne, and is highly safe for the human body.
[0006]
[Means for Solving the Problems]
The present inventors have studied paying attention to quantitative changes in proteases involved in keratinocyte detachment, and found that certain animal and plant extracts increase the amount of cathepsin D in cultured epidermal cells, and these are formulated. The present inventors have found that the obtained composition promotes exfoliation of the stratum corneum and exhibits an excellent acne prevention and treatment effect, thereby completing the present invention.
[0007]
That is, the present invention is, Mallotus japonicus, Karokon, Goshitsu, Sankirai, Hange, senega, calamus, honeysuckle, Sapindaceae, Butcher Bloom, bellflower, littoralis, tomato, loofah, avocado, cinchona, juniper, lettuce, Iris, high bone, shiitake, pepper and there is provided one or more consisting of plant extracts acne prophylactic therapeutic agent or desquamating accelerator selected from melilot.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
Plants in the plant extract of the present invention (A) include red-crowned wrinkles (Mallotus japonicus MUELL, Euphorbiaceae), otters (Arctostaphylos uwa-ursi Sprengel, azalea), calacons (Trichosanthes kirilowii Maximocz, Trichosanthes kirillvarii Maximocz. kitamura, or Trichosanthes bracteata Voigt, cucumber) Senega (Polygala senega L.), Ginger (Acorus Calamus L., Araceae), Honeysuckle (Lonicera japonica Thunb.), Mukuroji (Sapindus mukurossi Gaertn., Aspalathidae linearis) .Dahlgr, legume), butcher bloom (Nagiikada) Ruscus aculeatus L., Lily family), Engosaku (Corydalis turtschaninouii Besser or other congeneric plant, Papaveraceae), Pepper (Platycodon grandinorum A. De Candolle, Papaveraceae), Hamabofu (Glehnia Littoralis Fr. Schmidt, Prunus) Murasaki Lithospermum erythrorhizon Siebold, Tomato (Lycopersicum esculentum Mill., Solanumaceae), Loofah (Luftacyundrbca Roem., Cucurbitaceae), Lemon (Citrus limon Burmann fil. , Cuckoo (Pueraria lobata ohwi, leguminous), hawthorn (Crataeus oxyacantha L., Rosaceae), calendula (Calendula officinalis L., asteraceae), hamamelis (Hamamelis virginiana L., licorice) , Grapes (Vitis vinifera L., Grapeaceae), Bodaige (Tilla cordata Miller, Lindenaceae), Melissa (Melassaceae Melissa officinalis L., Labiatae), Malo D (horse chestnut Aesculus Hippocastanum L., Aesculus), avocado (Persea americana Mill. , Cinchona succirubra Pavon et Klotzch or other congeneric plants, Rubiaceae, Juniperus communis L., Cypressaceae, Rosaroxburghii Tratt. F. Jormalis Rehd et Wils, Lettuce (Lactuca sativa L, Asteraceae), Iris (Iris florentina L., Iridaceae), Koupone (Nuphar japonicum DC., Lilyaceae), Shiitake (Lentinas ebobes Singer), Clover (Centella asiatica L.) ), Red pepper (Capsicum annuum L., solanaceae), and merilotus (Melilotus officinalis L., legume).
[0009]
These plants can be used for red bark, walnut leaves, roots excluding calocon skin, gothic roots, sankirai tuberous roots, tuber roots excluding Hange cork layer, senegal roots, ginger roots, honeysuckle Flowers, leaves and stems, fruit of black croaker, whole plant of asparagus linen alice, rhizome of butcher bloom, engosac tuber root, yellow root, rhododendron root and rhizome, purple root, tomato fruit (raw), loofah fruit (Raw), lemon fruit (raw), Altea roots and leaves, roots excluding persimmon pericarp, hawthorn flowers / leaves / fruits, flowers of eucalyptus, leaves / branches and bark of clams, grape Leaves, Bodaige flowers, Melissa leaves, Marronnier leaves and bark, avocado fruit (raw), linden bark, apricot fruit, Izayou rose Fruits, lettuce leaves, Iris rhizome, rhizome of high bone, shiitake fruiting, leaves and stems of Centella asiatica, pepper fruits, aerial parts of melilot is preferred.
Further, it can be obtained as a concentrated extract or a dry powder by immersing or heating under reflux with an appropriate extraction solvent, and appropriately filtering, concentrating and freeze-drying.
[0010]
As extraction solvents, commonly used organic solvents such as methanol, ethanol, propanol, butanol, ether, ethylene glycol, propylene glycol, butylene glycol, hexane, heptane, cyclohexane, ethyl acetate, acetone, toluene, dichloroethane, chloroform, and water 1 type of these can be used individually or in mixture of 2 or more types. Among these solvents, polar solvents are preferable, and ethanol, water, propylene glycol, and butylene glycol are particularly preferable.
[0011]
The extraction treatment can usually be carried out at a temperature of about 3 to 100 ° C. for several hours to several weeks by a conventional method. Separation and purification of the active ingredient from the extract is performed by gel filtration, column chromatography, precision distillation of the extract. Etc.
[0012]
The chlorella in the (B) chlorella extract of the present invention refers to a substantially spherical unicellular green algae having a diameter of 3 to 10 microns classified into the genus Oocystaceae Chlorella, and the species is not particularly limited. For example, Chlorella vulgaris, Chlorella pyrenoidosa, Chlorella regularis, etc. Among them, Chlorella vulgaris is preferable.
The chlorella extract can be obtained by extracting the chlorella alga body (total algae) according to the above-mentioned plant extraction method. In particular, it can be extracted and concentrated using water, ethanol, or a mixed solvent of both. preferable.
[0013]
The (C) placenta extract of the present invention is a method of washing a placenta of a mammal such as a cow, pig or human, and extracting water-soluble components through means such as blood removal, crushing and freezing, and further removing impurities. Can be obtained. These are generally marketed as water-soluble placenta extracts and used as cosmetic raw materials. From the viewpoint of acne prevention treatment, bovine placenta extract is preferred.
[0014]
The thus-obtained extracts (A) to (C) of the present invention have the action of promoting the production of cathepsin D, a protease derived from the lamellar granules of epidermal cells, as shown in Examples below, and promote the peeling of the stratum corneum And suppresses the formation of experimental acne. Therefore, a preparation containing the extract is useful as a medicine or cosmetic for the purpose of preventing and treating acne.
[0015]
When the acne prevention / treatment agent or stratum corneum peeling promoter of the present invention is used as a medicine, it can be a tablet, capsule, ointment, liquid, extract, lotion, emulsion, etc. Use as is preferred. For example, in the case of an ointment, it may be one based on an oily base, or one based on an oil-in-water or water-in-oil emulsified base. Examples of oily bases include: Examples include vegetable oils, animal oils, synthetic oils, fatty acids and natural or synthetic glycerides.
[0016]
In addition, other medicinal components such as analgesic / anti-inflammatory agents, bactericidal / disinfectant agents, astringents, emollients, hormone agents, and the like can be appropriately added to the medicine as necessary.
[0017]
When used as a cosmetic, in addition to the extract of the present invention, oils, surfactants, UV absorbers, whitening agents, alcohols, chelating agents, pH adjusters, antiseptics generally used as cosmetic ingredients Agents, thickeners, pigments, fragrances, various skin nutrients, and the like can be combined in any combination.
[0018]
Cosmetics may be in various forms, for example, water-in-oil or oil-in-water emulsified cosmetics, creams, gels, cosmetic emulsions, lotions, oily cosmetics, facial cleansers, foundations, packs, and the like. it can.
[0019]
The compounding amount of the active ingredient in the medicine or cosmetic is usually 0.01 to 20% by weight, particularly 0.1 to 10% by weight of the total composition as a dry product.
[0020]
【Example】
Production Example 1 Preparation of Butcher Bloom Extract Cut root of butcher bloom (Nagiikada Ruscus aculeatus L., Lilyaceae), add 10 mL of water and ethanol mixture (70:30) to 10 g, and at 50 ° C, occasionally. The mixture was extracted with stirring for 5 hours and then filtered. This was left to stand at 5 ° C. for 7 days for aging, and the resulting sediment and precipitate were filtered. To this was added a mixture of water and ethanol (70:30) to make a total of 100 mL.
[0021]
Production Example 2
According to Production Example 1, 100 mL of various extracts shown in Table 1 were prepared.
In addition, “Falcolex BPS” was used as the bovine placenta extract.
[0022]
[Table 1]
[0023]
Example 1 Promotion of cathepsin D production in cultured epidermal cells Normal human epidermal cells (Kyokuto Pharmaceutical) were treated with various extracts shown in Table 2 at 0.1 and 1.0% concentrations (addition concentrations of extracts) Cathepsin D, a lamellar granule-derived protease that was released inside, was detected by Western blotting, and the intensity of the band was compared with that of the control. The results are shown in Table 2 as the average of 3 trials.
[0024]
[Table 2]
[0025]
From these results, it was shown that the various extracts of the present invention promote the production of cathepsin D in epidermal cells, suggesting that they have an action of promoting detachment of the stratum corneum.
[0026]
Example 2 Peeling promotion effect on human stratum corneum After 5% dansyl chloride solution was applied to human arm skin for 1 day, plant extracts of various concentrations shown in Table 3 were applied for 9 days, and the intensity of fluorescence at the application site Was visually determined and evaluated according to the following evaluation criteria. The results are shown in Table 3.
<Evaluation criteria>
+++: Strong fluorescence is observed in the whole ++: Fluorescence is observed in the whole +: Weak fluorescence is recognized ±: Slight fluorescence is observed-: No fluorescence is observed [0027]
[Table 3]
[0028]
From Table 3, it was shown that the extinction of fluorescence by dansyl chloride in the stratum corneum was recognized and the exfoliation of the stratum corneum was promoted by application of the plant extract of the present invention.
[0029]
Examples 3 to 51 Experimental Acne Formation Inhibitory Action 153 New Zealand white rabbits (male, body weight around 2.5 kg) were divided into 51 groups (n = 3). In each group, 50% tetradecane squalane solution was applied once in the morning and 70% ethanol once in the afternoon for 14 days, and used as a control side. On the other hand, a 50% tetradecane squalane solution was applied in the morning to the ear canal of the right ear external auditory canal, and a 70% ethanol solution of various extracts shown in Tables 4 to 6 was applied in the afternoon in the same manner as the sample side ( The concentration of each extract is expressed as the evaporation residue concentration (W / V%) of the extract). The experimental acne that formed in the ears on both sides was observed with a microscope, the area of the pore eruption was measured (10 points on each side), and the degree of improvement was compared between the left and right ears. The results (degree of improvement of the right ear relative to the left ear) are also shown in Tables 4-6.
[0030]
[Table 4]
[0031]
[Table 5]
[0032]
[Table 6]
[0033]
From this, it was shown that the extracts (A) to (C) of the present invention suppress the formation of acne.
[0034]
【The invention's effect】
The acne preventive and therapeutic agent and stratum corneum exfoliation promoter of the present invention are highly safe for the human body and are effective in preventing and treating acne by promoting exfoliation of the stratum corneum from the daily skin care stage. Useful.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000140031A JP4589483B2 (en) | 2000-05-12 | 2000-05-12 | Acne preventive and therapeutic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000140031A JP4589483B2 (en) | 2000-05-12 | 2000-05-12 | Acne preventive and therapeutic agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001322943A JP2001322943A (en) | 2001-11-20 |
JP4589483B2 true JP4589483B2 (en) | 2010-12-01 |
Family
ID=18647387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000140031A Expired - Lifetime JP4589483B2 (en) | 2000-05-12 | 2000-05-12 | Acne preventive and therapeutic agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4589483B2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002222747A1 (en) * | 2000-12-12 | 2002-06-24 | Angiolab, Inc. | Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
DE50211883D1 (en) * | 2002-04-30 | 2008-04-24 | Cognis Ip Man Gmbh | Use of active substance mixtures with azelaic acid and glycyrrhetinic acid as anti-acne agents |
AU2002950308A0 (en) * | 2002-07-23 | 2002-09-12 | Phoenix Eagle Company Pty Ltd | Topically applied composition |
AU2002327094A1 (en) * | 2002-08-14 | 2004-03-03 | Fancl Corporation | Cosmetics |
KR100552245B1 (en) * | 2003-10-24 | 2006-02-14 | 주식회사 코리아나화장품 | Cosmetic Compositions Comprising Extract from Mallotus japonicus for Improving Skin Wrinkle |
DE10353607A1 (en) * | 2003-11-17 | 2005-06-16 | Beiersdorf Ag | Jelaengerjelieber (especially Lonicera japonica (Japanese honeysuckle)) flower extract is used in after-shave compositions to treat shaving-induced skin and connective tissue damage |
JP2005200334A (en) * | 2004-01-15 | 2005-07-28 | Ichimaru Pharcos Co Ltd | Method for preventing or ameliorating skin aging or skin disease |
JP4892857B2 (en) * | 2004-04-15 | 2012-03-07 | 大正製薬株式会社 | Preventive or ameliorating agent for menopause |
JP4892856B2 (en) * | 2004-04-15 | 2012-03-07 | 大正製薬株式会社 | Female hormone balance regulator |
FR2869541B1 (en) * | 2004-04-30 | 2007-12-28 | Expanscience Sa Lab | USE OF A COMPOSITION COMPRISING D-MANNOHEPTULOSE AND / OR PERSEITOL FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH A CHANGE IN INITIATED IMMUNITY |
KR100630410B1 (en) * | 2005-04-18 | 2006-10-12 | 이화여자대학교 산학협력단 | Topical compositions of herbal extracts for prevention and cure of acne |
DE102005019653A1 (en) * | 2005-04-26 | 2006-11-02 | Henkel Kgaa | Plant extracts for halitosis, gingivitis or periodontitis |
JP2007204414A (en) * | 2006-02-01 | 2007-08-16 | Jukobi Kk | Cosmetic composition and cosmetic for improving acne |
KR101305972B1 (en) * | 2006-10-19 | 2013-09-12 | (주)아모레퍼시픽 | Cosmetic composition for swelling blackheads on the skin |
AR060847A1 (en) * | 2007-05-03 | 2008-07-16 | Spannagel Lucia Antonia | FORMULATION BASED ON CALENDULA, ALOE AND CENTELLA. |
JP4526575B2 (en) * | 2007-08-06 | 2010-08-18 | 株式会社メタルカラー | Chlorella extract-containing beverage |
JP5463667B2 (en) * | 2008-12-25 | 2014-04-09 | 株式会社スタイリングライフ・ホールディングス | Topical skin preparation |
JP5732207B2 (en) * | 2010-07-02 | 2015-06-10 | 花王株式会社 | VEGF production promoter |
DK2648809T3 (en) | 2010-12-09 | 2019-07-15 | Y&B Mothers Choice Ltd | NATURAL FORMULATIONS |
US10434058B2 (en) | 2010-12-09 | 2019-10-08 | Y&B Mother's Choice Ltd. | Natural formulations |
CA2858505A1 (en) | 2010-12-09 | 2012-06-14 | Y&B Mother's Choice Ltd. | Formulations comprising saponins and uses thereof |
FR2969496B1 (en) * | 2010-12-22 | 2013-11-08 | Expanscience Lab | EXTRACT OF PULP AND / OR AVOCADO SKIN RICH IN POLYPHENOLS AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME |
US20140154342A1 (en) * | 2011-07-28 | 2014-06-05 | Santalis Pharmaceuticals Inc. | Sandalwood oil and its uses related to skin disorders |
JP5283741B2 (en) * | 2011-10-05 | 2013-09-04 | 一丸ファルコス株式会社 | Trypsin inhibitor |
CN102935129B (en) * | 2012-09-30 | 2014-08-27 | 广西梧州三鹤药业有限公司 | Pharmaceutical composition for cleaning and removing acne and preparation method of pharmaceutical composition |
CN102920787A (en) * | 2012-11-26 | 2013-02-13 | 王丹 | Traditional Chinese medicine for treating acne |
JP2014118366A (en) * | 2012-12-13 | 2014-06-30 | Pola Chem Ind Inc | Advanced glycation end product decomposer |
US9861670B2 (en) | 2013-03-13 | 2018-01-09 | Santalis Healthcare Corporation | Stabilized cream formulations comprising sandalwood oil |
TWI663982B (en) * | 2013-09-03 | 2019-07-01 | 合一生技股份有限公司 | Use of hand-fragrant extract for preparing antimicrobial composition |
IL229836A0 (en) | 2013-12-08 | 2014-03-31 | Y & B Mother S Choice Ltd | Preparations for suppressing or attenuating ocular irritancy |
CN103800727A (en) * | 2014-03-07 | 2014-05-21 | 柯利佳 | Acne removing composition prepared from medicine-food homologous medicinal materials fully |
JP2015229649A (en) * | 2014-06-05 | 2015-12-21 | ポーラ化成工業株式会社 | hBD-3 EXPRESSION LEVEL IMPROVER |
CN104666721A (en) * | 2015-03-30 | 2015-06-03 | 张鹏 | Medicinal composition for treating acne |
CN104800310B (en) * | 2015-05-22 | 2018-01-30 | 湖南中医药大学 | Burn and scald external Chinese medicine ointment preparation and preparation method thereof |
WO2017062631A1 (en) | 2015-10-07 | 2017-04-13 | Santalis Pharmaceuticals, Inc. | Sandalwood oil and its uses related to oral mucositis |
JP6732495B2 (en) * | 2016-03-30 | 2020-07-29 | 小林製薬株式会社 | Composition for suppressing sebum secretion |
JP2016199550A (en) * | 2016-05-17 | 2016-12-01 | ピアス株式会社 | EXPRESSION ACTIVATOR OF Bmal1 GENE AND EXPRESSION ACTIVATION METHOD OF Bmal1 GENE |
JP6611212B2 (en) * | 2018-07-12 | 2019-11-27 | ポーラ化成工業株式会社 | Acne-improving composition |
CN109481602B (en) * | 2018-12-21 | 2021-10-01 | 河南大学 | Traditional Chinese medicine composition for effectively treating acne and preparation method thereof |
JP7316647B2 (en) * | 2019-07-16 | 2023-07-28 | 日本メナード化粧品株式会社 | Cathepsin V activity promoter and GATA-3 production inhibitor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000128766A (en) * | 1998-10-26 | 2000-05-09 | Saburo Uchikuga | Skin-whitening cosmetic |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2684179B2 (en) * | 1987-12-21 | 1997-12-03 | 雪印乳業株式会社 | Anti-inflammatory agent |
JP2819033B2 (en) * | 1989-09-07 | 1998-10-30 | 一丸ファルコス株式会社 | An external preparation for skin or hair or a cosmetic containing a growth inhibitor of Propionibacterium acnes |
JP2962558B2 (en) * | 1989-12-15 | 1999-10-12 | 株式会社資生堂 | Cosmetics |
JP2709546B2 (en) * | 1991-12-27 | 1998-02-04 | 株式会社ユニエ | A therapeutic agent for improving tissue disorders due to skin diseases and immune reactions |
JP3611128B2 (en) * | 1992-03-13 | 2005-01-19 | 株式会社資生堂 | Testosterone-5-α-reductase inhibitor |
JPH0725742A (en) * | 1993-07-15 | 1995-01-27 | Kao Corp | Fair-skinning cosmetic |
JPH0940523A (en) * | 1995-07-28 | 1997-02-10 | Ichimaru Pharcos Co Ltd | Fibroblast proliferation promoter containing water extract form chlorella |
JPH0987128A (en) * | 1995-09-20 | 1997-03-31 | Tsumura & Co | Capsule having sebum absorptivity and dermal preparation for external use containing the same capsule |
JPH09241146A (en) * | 1996-03-06 | 1997-09-16 | Noevir Co Ltd | Skin external agent |
JP4104180B2 (en) * | 1996-05-08 | 2008-06-18 | 一丸ファルコス株式会社 | Lipase activity promoter |
JPH09301884A (en) * | 1996-05-15 | 1997-11-25 | Ichimaru Pharcos Co Ltd | Testosterone 5 alpha-reductase inhibitor containing blackberry lily extract and alpha-hydroxyl acid and its application |
JPH09301880A (en) * | 1996-05-17 | 1997-11-25 | Noevir Co Ltd | Preparation for external use for skin |
JP3389071B2 (en) * | 1997-09-04 | 2003-03-24 | 花王株式会社 | Cosmetics |
JPH1143425A (en) * | 1997-07-28 | 1999-02-16 | Nippon Bio Kk | External preparation for skin |
JP4197194B2 (en) * | 1997-10-08 | 2008-12-17 | 花王株式会社 | Oral administration agent for intercellular adhesion suppression |
FR2777183B1 (en) * | 1998-04-10 | 2001-03-02 | Oreal | USE OF AT LEAST ONE HYDROXYSTILBENE IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN AND COMPOSITION COMPRISING SAME |
-
2000
- 2000-05-12 JP JP2000140031A patent/JP4589483B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000128766A (en) * | 1998-10-26 | 2000-05-09 | Saburo Uchikuga | Skin-whitening cosmetic |
Also Published As
Publication number | Publication date |
---|---|
JP2001322943A (en) | 2001-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4589483B2 (en) | Acne preventive and therapeutic agent | |
KR101478945B1 (en) | Shampoo composition containing native plant extracts and natural oriental material extracts | |
JP5922715B2 (en) | Composition for controlling and / or stabilizing conditions affecting the skin | |
JP3415197B2 (en) | External preparation for skin | |
JPH0940523A (en) | Fibroblast proliferation promoter containing water extract form chlorella | |
KR100960054B1 (en) | Hair cosmetic composition for improving stste of scalp and preventing fall-out of hair | |
JPH0717847A (en) | Skin external preparation | |
JPH08119825A (en) | Hydroxytyrosol, application for skin external medicine or bathing agent | |
JP4104180B2 (en) | Lipase activity promoter | |
JPH09110710A (en) | Dermal preparation for external use and bathing agent | |
JP3407935B2 (en) | External preparation for skin | |
JP2000169383A (en) | Antiallergic agent | |
JP3563089B2 (en) | External preparation for skin | |
KR20200088074A (en) | Skin external composition comprising centella asiatica extract and papaver rhoeas extract | |
KR101827771B1 (en) | Cosmetic composition containing Broussonetia extract for improving acne | |
KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
JPH09194385A (en) | Antiallergic agent and preparation for external use for skin or bathing agent blended with the same agent | |
KR20140145278A (en) | Cosmetic composition containing Cimicifuga heracleifolia extract, Cornus officinalis extract and Geranium nepalense extract for skin convergence and elasticity effect | |
KR101009766B1 (en) | Cosmetic Composition containing the Extract of prunella vulgaris and Artemisia abrotanum for Improvement of Wrinkle | |
KR101418366B1 (en) | Composition containing bee venom and propolis for preventing or treating acne | |
MX2011004149A (en) | A topical composition comprising extracts of a. indica and m. charantia or s. indicum. | |
KR20150086922A (en) | Composition for relieving skin irritation and moisturizing skin containing natural fermented pine leaf extract | |
KR101852510B1 (en) | Cosmetic Composition Containing Broussonetia Extract for Inhibiting Lipogenesis and Decreasing Sebum Secretion of Skin | |
JP3319870B2 (en) | Skin external composition and bath agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060317 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060404 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060605 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061219 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100816 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100910 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4589483 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |